VYNE THERAPEUTICS INC (VYNE) Fundamental Analysis & Valuation

NASDAQ:VYNE • US92941V3087

Current stock price

0.5912 USD
-0.03 (-4.26%)
At close:
0.576 USD
-0.02 (-2.57%)
After Hours:

This VYNE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. VYNE Profitability Analysis

1.1 Basic Checks

  • VYNE had negative earnings in the past year.
  • In the past year VYNE has reported a negative cash flow from operations.
  • VYNE had negative earnings in each of the past 5 years.
  • VYNE had a negative operating cash flow in each of the past 5 years.
VYNE Yearly Net Income VS EBIT VS OCF VS FCFVYNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M -250M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -87.81%, VYNE is doing worse than 74.61% of the companies in the same industry.
  • With a Return On Equity value of -95.38%, VYNE is not doing good in the industry: 62.69% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -87.81%
ROE -95.38%
ROIC N/A
ROA(3y)-58.82%
ROA(5y)-68.56%
ROE(3y)-67.97%
ROE(5y)-85.75%
ROIC(3y)N/A
ROIC(5y)N/A
VYNE Yearly ROA, ROE, ROICVYNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VYNE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VYNE Yearly Profit, Operating, Gross MarginsVYNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. VYNE Health Analysis

2.1 Basic Checks

  • VYNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for VYNE has been increased compared to 1 year ago.
  • The number of shares outstanding for VYNE has been increased compared to 5 years ago.
  • There is no outstanding debt for VYNE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VYNE Yearly Shares OutstandingVYNE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
VYNE Yearly Total Debt VS Total AssetsVYNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • VYNE has an Altman-Z score of -32.15. This is a bad value and indicates that VYNE is not financially healthy and even has some risk of bankruptcy.
  • VYNE's Altman-Z score of -32.15 is on the low side compared to the rest of the industry. VYNE is outperformed by 86.53% of its industry peers.
  • There is no outstanding debt for VYNE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -32.15
ROIC/WACCN/A
WACC9.53%
VYNE Yearly LT Debt VS Equity VS FCFVYNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

2.3 Liquidity

  • VYNE has a Current Ratio of 12.53. This indicates that VYNE is financially healthy and has no problem in meeting its short term obligations.
  • VYNE has a better Current ratio (12.53) than 82.38% of its industry peers.
  • A Quick Ratio of 12.53 indicates that VYNE has no problem at all paying its short term obligations.
  • The Quick ratio of VYNE (12.53) is better than 82.38% of its industry peers.
Industry RankSector Rank
Current Ratio 12.53
Quick Ratio 12.53
VYNE Yearly Current Assets VS Current LiabilitesVYNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. VYNE Growth Analysis

3.1 Past

  • VYNE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.80%, which is quite impressive.
  • The Revenue has grown by 13.77% in the past year. This is quite good.
  • Measured over the past years, VYNE shows a very negative growth in Revenue. The Revenue has been decreasing by -51.38% on average per year.
EPS 1Y (TTM)34.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.67%
Revenue 1Y (TTM)13.77%
Revenue growth 3Y5.9%
Revenue growth 5Y-51.38%
Sales Q2Q%54.76%

3.2 Future

  • The Earnings Per Share is expected to grow by 5.94% on average over the next years.
  • Based on estimates for the next years, VYNE will show a very strong growth in Revenue. The Revenue will grow by 219.58% on average per year.
EPS Next Y-52.27%
EPS Next 2Y-65.71%
EPS Next 3Y-59.75%
EPS Next 5Y5.94%
Revenue Next Year16.67%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y219.58%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VYNE Yearly Revenue VS EstimatesVYNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2029 2030 2031 2032 2033 50M 100M 150M 200M
VYNE Yearly EPS VS EstimatesVYNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

0

4. VYNE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VYNE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VYNE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VYNE Price Earnings VS Forward Price EarningsVYNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VYNE Per share dataVYNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • VYNE's earnings are expected to decrease with -59.75% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-65.71%
EPS Next 3Y-59.75%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VYNE Dividend Analysis

5.1 Amount

  • VYNE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VYNE Fundamentals: All Metrics, Ratios and Statistics

VYNE THERAPEUTICS INC

NASDAQ:VYNE (3/27/2026, 8:00:01 PM)

After market: 0.576 -0.02 (-2.57%)

0.5912

-0.03 (-4.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-27
Earnings (Next)05-06
Inst Owners26.82%
Inst Owner Change106.98%
Ins Owners1.21%
Ins Owner Change-1.66%
Market Cap19.70M
Revenue(TTM)570.00K
Net Income(TTM)-26.48M
Analysts78
Price Target3.32 (461.57%)
Short Float %0.67%
Short Ratio0.52
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.15%
Min EPS beat(2)-28.21%
Max EPS beat(2)38.5%
EPS beat(4)3
Avg EPS beat(4)21.4%
Min EPS beat(4)-28.21%
Max EPS beat(4)42.93%
EPS beat(8)5
Avg EPS beat(8)12.42%
EPS beat(12)7
Avg EPS beat(12)-1.4%
EPS beat(16)10
Avg EPS beat(16)2.11%
Revenue beat(2)1
Avg Revenue beat(2)14.71%
Min Revenue beat(2)-36.27%
Max Revenue beat(2)65.69%
Revenue beat(4)2
Avg Revenue beat(4)67.65%
Min Revenue beat(4)-54.9%
Max Revenue beat(4)296.08%
Revenue beat(8)4
Avg Revenue beat(8)38.73%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 34.56
P/FCF N/A
P/OCF N/A
P/B 0.71
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.93
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.99
OCFYN/A
SpS0.02
BVpS0.83
TBVpS0.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -87.81%
ROE -95.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.82%
ROA(5y)-68.56%
ROE(3y)-67.97%
ROE(5y)-85.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.53
Quick Ratio 12.53
Altman-Z -32.15
F-Score5
WACC9.53%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.67%
EPS Next Y-52.27%
EPS Next 2Y-65.71%
EPS Next 3Y-59.75%
EPS Next 5Y5.94%
Revenue 1Y (TTM)13.77%
Revenue growth 3Y5.9%
Revenue growth 5Y-51.38%
Sales Q2Q%54.76%
Revenue Next Year16.67%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y219.58%
EBIT growth 1Y31.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-41.82%
EBIT Next 3Y-19.69%
EBIT Next 5YN/A
FCF growth 1Y2.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.5%
OCF growth 3YN/A
OCF growth 5YN/A

VYNE THERAPEUTICS INC / VYNE Fundamental Analysis FAQ

What is the fundamental rating for VYNE stock?

ChartMill assigns a fundamental rating of 3 / 10 to VYNE.


Can you provide the valuation status for VYNE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to VYNE THERAPEUTICS INC (VYNE). This can be considered as Overvalued.


Can you provide the profitability details for VYNE THERAPEUTICS INC?

VYNE THERAPEUTICS INC (VYNE) has a profitability rating of 0 / 10.


What is the earnings growth outlook for VYNE THERAPEUTICS INC?

The Earnings per Share (EPS) of VYNE THERAPEUTICS INC (VYNE) is expected to decline by -52.27% in the next year.